Clinical Trials Logo

Human Papillomavirus Infection clinical trials

View clinical trials related to Human Papillomavirus Infection.

Filter by:

NCT ID: NCT02827838 Completed - Clinical trials for Human Papillomavirus Infection

Durvalumab Before Surgery in Treating Patients With Oral Cavity or Oropharynx Cancer

Start date: January 2017
Phase: Phase 2
Study type: Interventional

This pilot clinical trial studies how well durvalumab before surgery works in treating patients with oral cavity or oropharynx cancer. Monoclonal antibodies, such as durvalumab, may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02785289 Completed - Clinical trials for Human Papillomavirus Infection

A Comparison of Cotton and Flocked Swabs for Vaginal Self Collection

Start date: June 2016
Phase: N/A
Study type: Interventional

The purpose of this study is to compare the performance of cotton and flocked swabs for vaginal self-sampling.

NCT ID: NCT02464358 Completed - Clinical trials for Human Papillomavirus Infection

An Information-Motivation-Behavioral Skills (IMB) Intervention to Promote Human Papillomavirus Vaccination Among Women

Start date: December 2011
Phase: N/A
Study type: Interventional

HPV infections are prominent among college-aged women. Although HPV vaccines decrease women's risk for cervical cancer, vaccination rates remain inadequate. This study explored the utility of an Information-Motivation-Behavioral Skills intervention in promoting HPV vaccination knowledge, motivation, and behavioral skills among college aged women.

NCT ID: NCT02460237 Completed - Clinical trials for Human Papillomavirus Infection

HPV Self-Test Intervention in Ohio Appalachia

Start date: November 2015
Phase: N/A
Study type: Interventional

This study will pilot test a culturally appropriate human papillomavirus (HPV) self-test intervention among women from Ohio Appalachia in order to determine the feasibility of HPV self-testing as a potential cervical cancer screening strategy. The intervention group will receive culturally appropriate materials and the control group will receive standard materials with their HPV self-test device.

NCT ID: NCT02355262 Completed - Breast Carcinoma Clinical Trials

CATCH-UP Intervention in Increasing Cancer Screening and Prevention Care in Uninsured Patients at Community Health Centers

Start date: July 1, 2014
Phase:
Study type: Observational

This randomized research trial studies the Community-based Health Information Technology (HIT) Tools for Cancer Screening and Health Insurance Promotion (CATCH-UP) intervention in increasing cancer screening and prevention care in uninsured patients at community health centers. The CATCH-UP intervention may contribute to increased rates of insurance coverage, leading to improved cancer screening and prevention rates in community health care settings, and general recommended preventive care.

NCT ID: NCT02188004 Completed - Clinical trials for Human Papillomavirus Infection

The Epidemiologic Study of Human Papillomavirus Infection and Related Diseases

Start date: June 2014
Phase:
Study type: Observational

primary purpose:Evaluate the prevalence and incidence of HPV infection and related diseases in subjects. Secondary purpose:Analyze risk factors of HPV infection and related diseases.

NCT ID: NCT01984697 Completed - Clinical trials for Human Papillomavirus Infection

A Phase III Study of a 2-dose Regimen of a Multivalent Human Papillomavirus (HPV) Vaccine (V503), Administered to 9 to 14 Year-olds and Compared to Young Women, 16 to 26 Years Old (V503-010)

Start date: December 12, 2013
Phase: Phase 3
Study type: Interventional

This was a 37-month safety and immunogenicity study conducted in boys and girls 9 to 14 years of age and in young women 16 to 26 years of age. From this study, the goal was to establish that the investigational 2-dose regimens (0, 6 months and 0, 12 months) studied in boys and girls 9 to 14 years of age are generally safe and immunogenic, with an antibody response that is not inferior to that observed in young women 16 to 26 years of age who received the standard 3-dose regimen of V503 (i.e., the population and dose regimen used to establish V503 efficacy).

NCT ID: NCT01932697 Completed - Clinical trials for Human Papillomavirus Infection

Radiation Therapy and Docetaxel in Treating Patients With HPV-Related Oropharyngeal Cancer

Start date: September 4, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well radiation therapy and docetaxel work in treating patients with human papillomavirus (HPV)-related oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving radiation therapy with docetaxel my kill more tumor cells.

NCT ID: NCT01702337 Completed - Clinical trials for Human Papillomavirus Infection

Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine

Start date: February 2010
Phase: N/A
Study type: Observational

This study compares the health and economic impact of the bivalent HPV vaccine (HPV-1) and the quadrivalent HPV vaccine (HPV-2).

NCT ID: NCT01694875 Completed - Clinical trials for Human Papillomavirus Infection

Clinical Evaluation of the APTIMA® HPV 16 18/45 Genotype Assay on the PANTHER® System

Start date: October 2012
Phase: N/A
Study type: Observational

The objective of the clinical study is to evaluate the AHPV-GT Assay using the PANTHER System in cervical cancer screening. This objective will be accomplished in the ASC-US Study by evaluating the performance characteristics of the AHPV-GT Assay using the PANTHER System in a sample population of women with ASC-US Pap test results who were 21 years of age or older ("≥21 years of age") at the time of their Pap visit. For the Adjunct Study, this objective will be accomplished by evaluating the ability of the AHPV-GT Assay using the PANTHER System to identify women at increased risk of cervical disease in a sample population of women with negative (NILM)cytology results who were ≥30 years of age at the time of their Pap visit.